{"receipt":{"id":"1aa1fdbe-6102-4d51-b200-1380b99e538d","status":"externally_anchored","status_note":"This receipt is signed by Preseen and externally timestamped by DigiCert RFC 3161 TSA.","payload_sha256":"9043cf34bed675bc1d18d84dbe0ba8ec86f97925fa2479a600035a52ddfd66d2","signature":"yv1fAmlAGJSXQ4z4oW1SoDEGFPBRZqLlHmuxHqRo6WQUBknDaNKKptTJYPoPI0uAM8ccmOfBKRxoTqZkraZ4Cw==","signature_algorithm":"ed25519","signature_encoding":"base64-raw-ed25519","public_key_id":"preseen-prod-ed25519-20260523","public_key":"CbFQINZmmv+VZJ9Ha23ibXpK8zz549ZcsMQNI8cha4g=","public_key_encoding":"base64-raw-ed25519","signed_at":"2026-10-19T22:59:26.551103+00:00","anchor_provider":"DigiCert RFC 3161 TSA","anchor_proof":{"type":"rfc3161_timestamp_token","policy":"2.16.840.1.114412.7.1","tsa_url":"http://timestamp.digicert.com","version":1,"gen_time":"2026-10-19T22:59:27+00:00","provider":"DigiCert RFC 3161 TSA","serial_number":"218224725299928027371791992114246365265","hash_algorithm":"sha256","token_der_base64":"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","response_der_base64":"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","message_imprint_sha256":"9043cf34bed675bc1d18d84dbe0ba8ec86f97925fa2479a600035a52ddfd66d2"},"anchored_at":"2026-10-19T22:59:27+00:00","payload_canonical_json":"{\"artifact\":{\"data_schema_version\":2,\"forecast_data\":{\"format\":\"probability_mass_function\",\"notes\":\"Synthesized ensemble forecast.\",\"payload\":{\"above_upper_probability\":0.0061531,\"bucket_edges\":[0.0,0.2,0.4,0.6,0.8,1.0,1.2,1.4,1.6,1.8,2.0,2.2,2.4,2.6,2.8,3.0,3.2,3.4,3.6,3.8,4.0,4.2,4.4,4.6,4.8,5.0,5.2,5.4,5.6,5.8,6.0,6.2,6.4,6.6,6.8,7.0,7.2,7.4,7.6,7.8,8.0,8.2,8.4,8.6,8.8,9.0,9.2,9.4,9.6,9.8,10.0,10.2,10.4,10.6,10.8,11.0,11.2,11.4,11.6,11.8,12.0,12.2,12.4,12.6,12.8,13.0,13.2,13.4,13.6,13.8,14.0,14.2,14.4,14.6,14.8,15.0,15.2,15.4,15.6,15.8,16.0,16.2,16.4,16.6,16.8,17.0,17.2,17.4,17.6,17.8,18.0,18.2,18.4,18.6,18.8,19.0,19.2,19.4,19.6,19.8,20.0,20.2,20.4,20.6,20.8,21.0,21.2,21.4,21.6,21.8,22.0,22.2,22.4,22.6,22.8,23.0,23.2,23.4,23.6,23.8,24.0,24.2,24.4,24.6,24.8,25.0,25.2,25.4,25.6,25.8,26.0,26.2,26.4,26.6,26.8,27.0,27.2,27.4,27.6,27.8,28.0,28.2,28.4,28.6,28.8,29.0,29.2,29.4,29.6,29.8,30.0,30.2,30.4,30.6,30.8,31.0,31.2,31.4,31.6,31.8,32.0,32.2,32.4,32.6,32.8,33.0,33.2,33.4,33.6,33.8,34.0,34.2,34.4,34.6,34.8,35.0,35.2,35.4,35.6,35.8,36.0,36.2,36.4,36.6,36.8,37.0,37.2,37.4,37.6,37.8,38.0,38.2,38.4,38.6,38.8,39.0,39.2,39.4,39.6,39.8,40.0],\"cumulative_distribution_function\":[0.0,0.00016717,0.00017896,0.00019276,0.00020883,0.00078461,0.00080615,0.00083092,0.00085928,0.00089162,0.00201317,0.00205467,0.00210139,0.00215376,0.00221222,0.00417891,0.00425086,0.00433019,0.00441733,0.00451265,0.00763117,0.00774394,0.00786591,0.00799737,0.00813855,0.01264757,0.01280881,0.01298032,0.01316223,0.01335465,0.0193886,0.01960234,0.01982689,0.0200624,0.02030902,0.02796548,0.02823504,0.02851656,0.02881046,0.0291173,0.03863736,0.03897208,0.03932201,0.03968816,0.04007166,0.05204449,0.05246659,0.05291016,0.0533768,0.05386816,0.06930284,0.06984888,0.07042493,0.07103277,0.07167414,0.09182203,0.09253545,0.09328717,0.09407854,0.09491076,0.12087216,0.12178891,0.12274893,0.12375263,0.12480016,0.15711256,0.1582474,0.1594253,0.16064556,0.16190734,0.20035537,0.20169697,0.20307662,0.20449293,0.20594444,0.24969877,0.25121613,0.2527641,0.25434113,0.2559457,0.30391492,0.30557015,0.3072486,0.30894889,0.31066972,0.36180774,0.36356583,0.3653407,0.36713109,0.36893576,0.42230195,0.42413128,0.42597088,0.42781928,0.42967493,0.48425218,0.48611723,0.48798423,0.4898512,0.49171603,0.54618501,0.54803891,0.54988383,0.55171734,0.55353698,0.60623535,0.60801975,0.60978282,0.61152213,0.61323535,0.66238906,0.66404347,0.66566544,0.66725314,0.66880496,0.71292661,0.71440254,0.71583891,0.71723492,0.71859003,0.7568355,0.75810801,0.75933927,0.76052959,0.76167948,0.79399082,0.79506206,0.79609541,0.79709199,0.79805303,0.82504408,0.82593811,0.82680079,0.8276336,0.82843805,0.85110501,0.85185721,0.85258547,0.8532912,0.85397576,0.87337142,0.87401743,0.8746459,0.8752579,0.87585438,0.89284356,0.89341156,0.89396642,0.89450876,0.8950391,0.91018813,0.9106958,0.91119263,0.91167888,0.91215474,0.92574313,0.9261986,0.92664397,0.92707929,0.92750455,0.9396106,0.94001566,0.94041057,0.94079527,0.94116971,0.95177626,0.95213003,0.95247341,0.95280637,0.95312891,0.96221132,0.96251303,0.96280439,0.96308545,0.96335627,0.97093524,0.97118591,0.97142669,0.97165772,0.97187917,0.97803885,0.97824168,0.9784355,0.97862053,0.97879699,0.98367781,0.98383786,0.98399006,0.98413468,0.98427197,0.98805031,0.98817373,0.9882906,0.98840118,0.98850574,0.99137069,0.99146396,0.99155194,0.9916349,0.99171306,0.9938469],\"percentiles\":{\"p10\":12.0,\"p50\":20.0,\"p90\":30.0},\"probability_mass_function\":[0.0,0.00016717244382714313,1.1790109333522435e-05,1.379694739526385e-05,1.6075012618078184e-05,0.0005757741977116725,2.1538503889975487e-05,2.4769777996577805e-05,2.8363079629910277e-05,3.233826506100018e-05,0.0011215486180749846,4.150250510461807e-05,4.671851352274757e-05,5.236932860389865e-05,5.8459133942015754e-05,0.0019666888214080695,7.19501305645968e-05,7.933674112618595e-05,8.71330622077933e-05,9.532001356631135e-05,0.0031185252869462025,0.0001127686765802769,0.00012197319111995479,0.00013145556247320532,0.00014118252576336013,0.004509022198254717,0.00016123959334783753,0.00017150984813925715,0.00018190804306010425,0.0001924166509468364,0.00603395406032847,0.00021373531914790548,0.00022455491495106984,0.00023550645608318656,0.00024662427625864544,0.007656456584296228,0.0002695620859748048,0.0002815170243627886,0.000293907396533365,0.0003068315461378066,0.009520061760465043,0.0003347236097727319,0.0003499312871994058,0.00036614740418374825,0.0003834988834312186,0.011972826724814544,0.00042209942900168427,0.00044357624447987905,0.0004666372723195626,0.0004913635883490287,0.015434675940210292,0.0005460406633321927,0.0005760504393485639,0.0006078396557614454,0.0006413747552666382,0.020147889390690624,0.0007134147849845902,0.0007517201118552822,0.0007913743972501427,0.0008322184078665702,0.025961403161030308,0.0009167442372666305,0.0009600232018859753,0.0010036937863893939,0.0010475349645217291,0.032312396382383764,0.001134847952910281,0.0011778932466359998,0.0012202639926186185,0.0012617781371496288,0.038448030612853214,0.0013416016915586693,0.0013796465793925973,0.0014163084467758546,0.001451512631553728,0.04375432541511861,0.001517362563739931,0.001547968048222588,0.0015770310841928341,0.0016045735116557076,0.04796921417015564,0.0016552368215305368,0.0016784435472233183,0.0017002939900113644,0.001720830328484138,0.051138019593415594,0.0017580939964044113,0.0017748618467902572,0.0017903921660049143,0.0018046700357010584,0.05336619507824956,0.0018293286969606995,0.0018396000904523618,0.0018484020829116403,0.0018556456574120388,0.0545772471681249,0.0018650541375606704,0.0018670024053777461,0.0018669655254227229,0.0018648353038044129,0.054468976761277106,0.0018538976539307194,0.0018449197216927615,0.0018335137809086187,0.0018196363648133205,0.05269837055191664,0.0017844007911014038,0.0017630679645829872,0.0017393162038921882,0.0017132199108200684,0.0491537026350345,0.0016544124814443116,0.0016219678232205102,0.0015877081609250387,0.0015518153928636813,0.04412165270708615,0.0014759303213159047,0.0014363650830550522,0.001396014574515031,0.0013551052270413476,0.03824547365366134,0.0012725095821665366,0.0012312608905364452,0.0011903229466783184,0.0011498901488797898,0.03231133390990335,0.0010712462613956808,0.0010333475640667833,0.0009965762282564072,0.0009610425506967001,0.026991049619257492,0.0008940321418923091,0.0008626789147460566,0.0008328111500264856,0.0008044443880093454,0.02266696504496034,0.0007521929537057936,0.0007282601163019542,0.0007057348370094973,0.0006845619949873815,0.019395659417598004,0.000646007172042129,0.000628473934322088,0.0006119938647361489,0.0005964805094776315,0.016989184352405987,0.0005680013131338757,0.0005548596917813952,0.0005423355727431634,0.0005303466582840033,0.015149029084998494,0.0005076654150522498,0.0004968306414666612,0.00048624719754760125,0.0004758579902083282,0.013588397609007524,0.0004554646536605311,0.0004453772526473887,0.0004353174395477832,0.00042525874147971153,0.012106044334767795,0.0004050669937157803,0.0003949082510713853,0.0003846985122150537,0.0003744364005505152,0.010606558905760195,0.0003537683310836204,0.0003433770929968105,0.00033296205214773943,0.000322536708873955,0.009082408977605566,0.0003017172676688495,0.0002913571764874445,0.00028105408729252047,0.0002708263838180791,0.007578966945842335,0.0002506704467645615,0.00024077801264399954,0.00023103213400177403,0.00022144893843082934,0.006159679846872523,0.00020283001225358533,0.0001938211160098513,0.00018502841148344552,0.00017646212201034573,0.004880822319037342,0.00016004295076677555,0.00015220377932482766,0.00014461847675117378,0.00013729062579621032,0.003778342890730224,0.00012341549601426748,0.00011686944827675183,0.0001105834501636871,0.0001045555544266441,0.0028649579405570277,9.326192748915774e-05,8.79881910511915e-05,8.295670922524588e-05,7.816191020214025e-05,0.002133839111250041],\"scale_type\":\"linear\"},\"question_type\":\"numeric\"},\"forecast_data_point_id\":\"636704e5-6157-4dd8-a45a-d96ea1ffe9bf\",\"generated_at\":\"2026-10-19T22:59:26.483218+00:00\",\"metadata\":{\"engine\":\"durable_forecast\",\"model\":\"gpt-6.1-sol\",\"model_route\":{\"deadline_seconds\":2400,\"managed_tools\":true,\"max_attempts\":2,\"metadata\":{},\"model\":\"gpt-6.1-sol\",\"native_code_execution\":true,\"native_web_search\":true,\"provider\":\"openai\",\"reasoning_effort\":\"xhigh\"},\"orchestration_backend\":\"durable_forecast\",\"provider\":\"openai\",\"question_type\":\"numeric\"},\"sources\":[{\"cutoff_date\":null,\"display_name\":\"Domain Expert Search\",\"first_seen_at\":\"2026-10-19T22:48:26.544973+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"Found 7 domain experts for 'US GLP-1 obesity medication adoption survey Gallup measurement current use versus ever use methodology 2026 forecasts 2030':\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"News\",\"first_seen_at\":\"2026-10-19T22:49:15.519328+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"Found 12 merged articles (asknews: 6, perigon: 6, both: 0).\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"fiercepharma.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519635+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519648+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/markets/stocks/articles/lly-stock-down-around-7-150800358.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"nature.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519656+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.nature.com/articles/s41591-026-04687-x\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519662+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/lly-around-6-post-robust-150900844.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"mmm-online.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519675+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.mmm-online.com/news/lilly-novo-awareness-medicare-glp-1-program\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519682+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/lly-stock-down-2-3-113100115.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"eu.delawareonline.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519695+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://eu.delawareonline.com/story/shopping/health-wellness/2026/10/12/affordable-glp-1-options-arbor-health/92214948007\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519700+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/novo-nordisk-q2-earnings-call-220350961.html\"},{\"cutoff_date\":null,\"display_name\":\"ca.style.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519706+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://ca.style.yahoo.com/glp-1-pills-are-finally-here-heres-the-tradeoff-nobodys-advertising-145500030.html\"},{\"cutoff_date\":null,\"display_name\":\"cnbc.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519713+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.cnbc.com/2026/09/25/novo-eli-lilly-obesity-drugs.html\"},{\"cutoff_date\":null,\"display_name\":\"247wallst.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519724+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://247wallst.com/personal-finance/social-security/2026/09/30/700000-seniors-have-started-glp-1s-through-medicare-now-astrazeneca-just-moved-a-once-daily-pill-into-phase-3\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:49:15.519730+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/sleep-apnea-clinical-trial-pipeline-170000702.html\"},{\"cutoff_date\":null,\"display_name\":\"Openfda\",\"first_seen_at\":\"2026-10-19T22:49:49.282660+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"Found 1 total applications. Showing 1:\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"Domain Expert Research Task\",\"first_seen_at\":\"2026-10-19T22:53:35.600963+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"Job domain_expert_research_task_1935c22bf4 done after 295743ms.\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"doi.org\",\"first_seen_at\":\"2026-10-19T22:53:35.601261+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://doi.org/10.18553/jmcp.2026.32.3.281\"},{\"cutoff_date\":null,\"display_name\":\"doi.org\",\"first_seen_at\":\"2026-10-19T22:53:35.601277+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://doi.org/10.64898/2026.08.28.26361368\"},{\"cutoff_date\":null,\"display_name\":\"jamanetwork.com\",\"first_seen_at\":\"2026-10-19T22:53:35.601286+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779\"},{\"cutoff_date\":null,\"display_name\":\"doi.org\",\"first_seen_at\":\"2026-10-19T22:53:35.601293+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://doi.org/10.2337/doc25-0026\"},{\"cutoff_date\":null,\"display_name\":\"doi.org\",\"first_seen_at\":\"2026-10-19T22:53:35.601300+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://doi.org/10.1002/osp4.70200\"},{\"cutoff_date\":null,\"display_name\":\"In U.S., GLP-1 Usage Reaches New High\",\"first_seen_at\":\"2026-10-19T22:48:07.338061+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx\"},{\"cutoff_date\":null,\"display_name\":\"Webarchive\",\"first_seen_at\":\"2026-10-19T22:34:23.655685+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"{\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:23.655888+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:23.655896+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260831155021/https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx\"},{\"cutoff_date\":null,\"display_name\":\"linkedin.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288577+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fnews.gallup.com%2Fpoll%2F712157%2Fglp-usage-reaches-new-high.aspx%3Futm_source%3Dlinkedinbutton%26utm_medium%3Dlinkedin%26utm_campaign%3Dsharing&title=In+U.S.%2C+GLP-1+Usage+Reaches+New+High&summary=GLP-1+medications+for+weight+loss+continue+to+grow+in+popularity%3A+15%25+of+U.S.+adults+have+now+tried+them%2C+as+obesity+rates+continue+to+decline.&source=https%3A%2F%2Fnews.gallup.com%2F\"},{\"cutoff_date\":null,\"display_name\":\"twitter.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288591+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://twitter.com/share?url=https%3A%2F%2Fnews.gallup.com%2Fpoll%2F712157%2Fglp-usage-reaches-new-high.aspx%3Futm_source%3Dtwitterbutton%26utm_medium%3Dtwitter%26utm_campaign%3Dsharing&text=In+U.S.%2C+GLP-1+Usage+Reaches+New+High\"},{\"cutoff_date\":null,\"display_name\":\"facebook.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288605+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fnews.gallup.com%2Fpoll%2F712157%2Fglp-usage-reaches-new-high.aspx%3Futm_source%3Dfacebookbutton%26utm_medium%3Dfacebook%26utm_campaign%3Dsharing&t=In+U.S.%2C+GLP-1+Usage+Reaches+New+High\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288618+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/mailto:?subject=Gallup%3A+In+U.S.%2C+GLP-1+Usage+Reaches+New+High&body=https%3A%2F%2Fnews.gallup.com%2Fpoll%2F712157%2Fglp-usage-reaches-new-high.aspx\"},{\"cutoff_date\":null,\"display_name\":\"gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288626+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.gallup.com/people/item.aspx?a=122408\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288632+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://news.gallup.com/poll/246200/gallup-national-health-index-work.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288639+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://www.gallup.com/174158/gallup-panel-methodology.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288645+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://news.gallup.com/poll/696599/obesity-rate-declining.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288652+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://news.gallup.com/poll/644861/injectable-weight-loss-drugs-uses-work.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288665+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://x.com/gallup\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288681+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://www.instagram.com/gallup\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288687+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://policies.google.com/privacy\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288694+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://policies.google.com/terms\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288700+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/country-usa.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288707+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/all-gallup-headlines.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288713+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/gallup-panel.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288720+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/category-health.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288726+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/health-habits.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288733+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/category-wellbeing.aspx\"},{\"cutoff_date\":null,\"display_name\":\"web.archive.org\",\"first_seen_at\":\"2026-10-19T22:34:34.288739+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://web.archive.org/web/20260903211304/https://www.gallup.com/analytics/213617/gallup-analytics.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288746+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/category_wellbeing.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288751+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/708221/depression-rate-remains-elevated.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288762+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/topic/politics.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288768+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/707732/healthcare-reclaims-top-spot-among-domestic-worries.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288774+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/699893/exercise-link-lower-stress-greater-women-men.aspx\"},{\"cutoff_date\":null,\"display_name\":\"news.gallup.com\",\"first_seen_at\":\"2026-10-19T22:34:34.288779+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/700112/half-americans-lose-weight.aspx\"},{\"cutoff_date\":null,\"display_name\":\"fda.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598330+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-treatment-obesity\"},{\"cutoff_date\":null,\"display_name\":\"cms.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598344+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.cms.gov/priorities/innovation/innovation-models/glp-1-bridge\"},{\"cutoff_date\":null,\"display_name\":\"cms.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598352+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.cms.gov/priorities/innovation/innovation-models/balance\"},{\"cutoff_date\":null,\"display_name\":\"clinicaltrials.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598360+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://clinicaltrials.gov/study/NCT06383390\"},{\"cutoff_date\":null,\"display_name\":\"clinicaltrials.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598374+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://clinicaltrials.gov/study/NCT05869903\"},{\"cutoff_date\":null,\"display_name\":\"clinicaltrials.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598382+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://clinicaltrials.gov/study/NCT06858839\"},{\"cutoff_date\":null,\"display_name\":\"clinicaltrials.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.598389+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://clinicaltrials.gov/study/NCT07104500\"},{\"cutoff_date\":null,\"display_name\":\"Claude Code\",\"first_seen_at\":\"2026-10-19T22:45:08.598702+00:00\",\"kind\":\"tool\",\"provider\":\"e2b\",\"snippet\":\"Job coding_whiz_job_56c27d32d2 done after 440282ms.\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"Obesity Rate Declining in U.S.\",\"first_seen_at\":\"2026-10-19T22:48:07.337907+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/696599/obesity-rate-declining.aspx\"},{\"cutoff_date\":null,\"display_name\":\"iqvia.com\",\"first_seen_at\":\"2026-10-19T22:45:08.599278+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.iqvia.com/es-gt/locations/united-states/blogs/2025/09/obesity-deep-dive-the-unparalleled-launch-success-of-mounjaro-and-zepbound\"},{\"cutoff_date\":null,\"display_name\":\"www.sec.gov\",\"first_seen_at\":\"2026-10-19T22:48:07.338095+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.sec.gov/Archives/edgar/data/353278/000035327826000023/caq22026.htm\"},{\"cutoff_date\":null,\"display_name\":\"2025 Employer Health Benefits Survey | KFF\",\"first_seen_at\":\"2026-10-19T22:48:07.338048+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.kff.org/health-costs/2025-employer-health-benefits-survey\"},{\"cutoff_date\":null,\"display_name\":\"CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications | CMS\",\"first_seen_at\":\"2026-10-19T22:43:37.147452+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications\"},{\"cutoff_date\":null,\"display_name\":\"novocare.com\",\"first_seen_at\":\"2026-10-19T22:45:08.599322+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.novocare.com/pharmacy/wegovy.html\"},{\"cutoff_date\":null,\"display_name\":\"bcg.com\",\"first_seen_at\":\"2026-10-19T22:45:08.599329+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bcg.com/publications/2026/glp-1-consumer-behavior-shift\"},{\"cutoff_date\":null,\"display_name\":\"How Supply and Demand for Weight Loss Drugs is Playing Out in 2026\",\"first_seen_at\":\"2026-10-19T22:48:07.338102+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs\"},{\"cutoff_date\":null,\"display_name\":\"Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists - PMC\",\"first_seen_at\":\"2026-10-19T22:48:07.337983+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759\"},{\"cutoff_date\":null,\"display_name\":\"cbo.gov\",\"first_seen_at\":\"2026-10-19T22:45:08.599364+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.cbo.gov/publication/57059\"},{\"cutoff_date\":null,\"display_name\":\"In U.S., GLP-1 Usage Reaches New High\",\"first_seen_at\":\"2026-10-19T22:48:07.337887+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx?trk=article-ssr-frontend-pulse_little-text-block\"},{\"cutoff_date\":null,\"display_name\":\"Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford | KFF\",\"first_seen_at\":\"2026-10-19T22:48:07.337912+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford?trk=article-ssr-frontend-pulse_little-text-block\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America Study | medRxiv\",\"first_seen_at\":\"2026-10-19T22:48:07.337963+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.medrxiv.org/content/10.64898/2026.08.28.26361368v1\"},{\"cutoff_date\":null,\"display_name\":\"Prime continues to lead industry on GLP-1 research: 1 in 7 stays on GLP-1 drugs for weight loss after two years - Prime Therapeutics - Portal\",\"first_seen_at\":\"2026-10-19T22:48:07.337973+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.primetherapeutics.com/w/prime-continues-to-lead-industry-on-glp-1-research-1-in-7-stays-on-glp-1-drugs-for-weight-loss-after-two-years?p_l_back_url=%2Fweb%2Fprimetherapeutics%2Fsearch%3Fcategory%3D10369645%26category%3D10371863%26category%3D10371878%26category%3D9726702%26delta%3D60%26q%3D%25E3%2580%2590HackerSite%253A%2BKunghac.com%25E3%2580%2591%252Ciphone%2Bhacks%2Btelegram%252Cwww%2Bhack%2Btelegram%2Bcom%252Cviptools%2Bes%2Bhack%2Btelegram%252Ctelegram%2Bfollowers%2Bhack%2Bgithub%252Ctelegram%2Bhack%2Bunlimited%2Bfollowers%2Bfree%252Ctelegram%2Bhacker%2Bsite%252Cwww%2Bzshadowave%2Bcom%2Btelegram%252Ctelegram%2Bhacker%2Bfor%2Bfree%252Chack%2Btelegram%2Bpassword%2Breset%252Ctelegram%2Bfollowers%2Bhack%2Bcom%252C%26start%3D1&p_l_back_url_title=Search\"},{\"cutoff_date\":null,\"display_name\":\"Weight maintenance after discontinuation of GLP-1 therapies - PMC\",\"first_seen_at\":\"2026-10-19T22:48:07.337992+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://pmc.ncbi.nlm.nih.gov/articles/PMC13240724\"},{\"cutoff_date\":null,\"display_name\":\"Wegovy\",\"first_seen_at\":\"2026-10-19T22:48:07.338023+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/218316Orig1s000Approv.pdf\"},{\"cutoff_date\":null,\"display_name\":\"Medicare GLP-1 Bridge | CMS\",\"first_seen_at\":\"2026-10-19T22:48:07.338036+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge\"},{\"cutoff_date\":null,\"display_name\":\"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial | Eli Lilly and Company\",\"first_seen_at\":\"2026-10-19T22:48:07.338072+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\"},{\"cutoff_date\":null,\"display_name\":\"FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide | FDA\",\"first_seen_at\":\"2026-10-19T22:48:07.338085+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide\"},{\"cutoff_date\":null,\"display_name\":\"Perigon\",\"first_seen_at\":\"2026-10-19T22:32:43.941433+00:00\",\"kind\":\"tool\",\"provider\":\"mcp\",\"snippet\":\"{\\\"total_results\\\": 10000, \\\"returned\\\": 10, \\\"articles\\\": [{\\\"id\\\": \\\"f9489674cf664ab1997a10467f7d7532\\\", \\\"title\\\": \\\"Health Brief: The fight over GLP-1 coverage\\\", \\\"source\\\": \\\"washingtonpost.com\\\", \\\"date\\\": \\\"2026-09-16\\\", \\\"url\\\": \\\"https://www.washingtonpost.com/wp-intelligence/health-brief/2026/09/16/health-brief-fight-over-glp-1-coverage/\\\", \\\"summary\\\": \\\"Plus: Nominee for surgeon general was pressed on vaccines as senators sought clarity on her views and how she would approach public health guidance.\\\", \\\"highligh…\",\"url\":null},{\"cutoff_date\":null,\"display_name\":\"washingtonpost.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941800+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.washingtonpost.com/wp-intelligence/health-brief/2026/09/16/health-brief-fight-over-glp-1-coverage\"},{\"cutoff_date\":null,\"display_name\":\"nbcnews.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941818+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.nbcnews.com/nightly-news/video/coverage-for-glp-1-denied-after-weight-loss-267846725530\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941827+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/glp-1-world-153842957.html\"},{\"cutoff_date\":null,\"display_name\":\"vox.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941835+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.vox.com/good-medicine-newsletter/506555/glp-1-wegovy-zepbound-cost-health-insurance\"},{\"cutoff_date\":null,\"display_name\":\"bostonglobe.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941850+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bostonglobe.com/2026/09/30/business/critics-glp1-coverage-equity\"},{\"cutoff_date\":null,\"display_name\":\"bloomberg.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941858+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bloomberg.com/news/audio/2026-09-24/everybody-s-business-insurance-and-glp-1-podcast?srnd=phx-businessweek\"},{\"cutoff_date\":null,\"display_name\":\"bostonglobe.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941871+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bostonglobe.com/2026/10/12/opinion/letters-insurers-restrict-weight-loss-drug-coverage\"},{\"cutoff_date\":null,\"display_name\":\"bizjournals.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941878+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bizjournals.com/atlanta/news/2026/08/13/glp-1s-weight-loss-drugs-dilemma-georgia-employers.html\"},{\"cutoff_date\":null,\"display_name\":\"bizjournals.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941885+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.bizjournals.com/buffalo/news/2026/08/01/helping-navigate-glp1-costs-access-employees.html\"},{\"cutoff_date\":null,\"display_name\":\"businessinsider.com\",\"first_seen_at\":\"2026-10-19T22:32:43.941893+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.businessinsider.com/starbucks-cuts-glp-1-coverage-weight-loss-costs-climb-2026-8\"},{\"cutoff_date\":null,\"display_name\":\"Injectable Weight Loss Drugs: Who Uses Them, and Do They Work?\",\"first_seen_at\":\"2026-10-19T22:43:37.147424+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://news.gallup.com/poll/644861/injectable-weight-loss-drugs-uses-work.aspx\"},{\"cutoff_date\":null,\"display_name\":\"KFF Health Tracking Poll - KFF Tracking Poll on Health Information and Trust - March 2026\",\"first_seen_at\":\"2026-10-19T22:43:37.147433+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf\"},{\"cutoff_date\":null,\"display_name\":\"KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use | KFF\",\"first_seen_at\":\"2026-10-19T22:43:37.147436+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use?trk=article-ssr-frontend-pulse_little-text-block\"},{\"cutoff_date\":null,\"display_name\":\"News details\",\"first_seen_at\":\"2026-10-19T22:43:37.147440+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.novonordisk-us.com/media/news-archive/news-details.html?cc=1010&id=916476&tc=soc_xid4ia\"},{\"cutoff_date\":null,\"display_name\":\"Wegovy® (semaglutide) Cost, Coverage, & Savings Resources | NovoCare®\",\"first_seen_at\":\"2026-10-19T22:43:37.147444+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.novocare.com/patient/medicines/wegovy.html\"},{\"cutoff_date\":null,\"display_name\":\"News Details\",\"first_seen_at\":\"2026-10-19T22:43:37.147448+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916504\"},{\"cutoff_date\":null,\"display_name\":\"Employers are shifting health care costs to employees but also leveraging new approaches to minimize impact\",\"first_seen_at\":\"2026-10-19T22:43:37.147455+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.mercer.com/en-us/about/newsroom/employers-are-shifting-healthcare-costs-to-employees?_sp=86c8cdf5-ea4f-4f90-a939-02749bfa3d22.1784557752005\"},{\"cutoff_date\":null,\"display_name\":\"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity | Nutrition, Obesity, Exercise | JAMA Network Open | JAMA Network\",\"first_seen_at\":\"2026-10-19T22:43:37.147459+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779?trk=public_post_comment-text\"},{\"cutoff_date\":null,\"display_name\":\"thestreet.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497537+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.thestreet.com/investing/stocks/lly-eli-lilly-ceo-ricks-foundayo-one-third-new-glp-1-pill-patients\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497544+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/walmart-wmt-launches-florida-drone-170947568.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"cnbc.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497552+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.cnbc.com/2026/08/01/glp-1-prescriptions-weight-loss-walmart-costco-amazon.html\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497558+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"finance.yahoo.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497571+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/eli-lillys-glp-1-portfolio-131500626.html?.tsrc=rss\"},{\"cutoff_date\":null,\"display_name\":\"ft.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497577+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.ft.com/content/b223f2d9-a4bf-43c3-9fc9-06d6c333bf6b\"},{\"cutoff_date\":null,\"display_name\":\"qz.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497583+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://qz.com/eli-lilly-medicare-weight-loss-drugs-ricks-092226\"},{\"cutoff_date\":null,\"display_name\":\"fool.com\",\"first_seen_at\":\"2026-10-19T22:32:25.497596+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fool.com/investing/2026/08/13/eli-lillys-glp-1-pricing-problem-is-actually-a-gro\"},{\"cutoff_date\":null,\"display_name\":\"files.kff.org\",\"first_seen_at\":\"2026-10-19T22:38:54.306687+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://files.kff.org/attachment/topline-kff-health-tracking-poll-nov-2025.pdf\"},{\"cutoff_date\":null,\"display_name\":\"Social Feeds Outpace Medical Advice as Primary Source for GLP-1 Drug Information | NORC at the University of Chicago\",\"first_seen_at\":\"2026-10-19T22:43:00.253699+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.norc.org/research/library/social-feeds-outpace-medical-advice-as-primary-source-for-glp-1-drug-information.html\"},{\"cutoff_date\":null,\"display_name\":\"medrxiv.org\",\"first_seen_at\":\"2026-10-19T22:38:54.306711+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.medrxiv.org/content/10.64898/2026.08.28.26361368v1.full\"},{\"cutoff_date\":null,\"display_name\":\"Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. | Eli Lilly and Company\",\"first_seen_at\":\"2026-10-19T22:43:00.253712+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://investor.lilly.com/news-releases/news-release-details/foundayotm-orforglipron-lillys-new-oral-glp-1-pill-weight-loss\"},{\"cutoff_date\":null,\"display_name\":\"novonordisk.com\",\"first_seen_at\":\"2026-10-19T22:43:00.253716+00:00\",\"kind\":\"web\",\"provider\":\"openai\",\"snippet\":null,\"url\":\"https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day/2026/gms-presentation-cmd-2026.pdf\"},{\"cutoff_date\":null,\"display_name\":\"Gallup on X: \\\"The percentage of U.S. adults who currently take GLP-1 medications for weight loss purposes has risen to 11% in 2026, up significantly from 3% in 2024. And 15% report having used the medicine for weight loss at some point, an increase of nine percentage points. https://t.co/9acjyhLUT1\\\" / X\",\"first_seen_at\":\"2026-10-19T22:47:49.691406+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://x.com/Gallup/status/2074500347112873990\"},{\"cutoff_date\":null,\"display_name\":\"1 in 9 Americans Now on GLP-1s\",\"first_seen_at\":\"2026-10-19T22:47:49.691414+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.medscape.com/viewarticle/1-9-americans-now-glp-1s-2026a1000nds\"},{\"cutoff_date\":null,\"display_name\":\"How Many Americans Are on Ozempic? GLP-1 Statistics 2026\",\"first_seen_at\":\"2026-10-19T22:47:49.691420+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://pabau.com/blog/glp-1-statistics\"},{\"cutoff_date\":null,\"display_name\":\"Americans are taking weight-loss drugs in record numbers - The Washington Post\",\"first_seen_at\":\"2026-10-19T22:47:49.691425+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.washingtonpost.com/health/2026/07/07/americans-are-taking-weight-loss-drugs-record-numbers\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Statistics and Trends for a Growing Market\",\"first_seen_at\":\"2026-10-19T22:47:49.691431+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://oakwoodlabs.com/glp-1-statistics-and-trends-for-a-growing-market\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Weight Loss Statistics 2026: Semaglutide & Tirzepatide Data, Market Size & Obesity Trends\",\"first_seen_at\":\"2026-10-19T22:47:49.691437+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://wellness.goalbmi.com/glp-1-statistics-2026\"},{\"cutoff_date\":null,\"display_name\":\"What percentage of US adults will claim to be currently taking GLP-1 drugs for weight loss in 2030? — Preseen\",\"first_seen_at\":\"2026-10-19T22:47:49.691442+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://preseen.com/questions/151c25d1-c058-4ba2-9d1b-a321baa33445\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Statistics 2026: Usage, Weight Loss & Cost\",\"first_seen_at\":\"2026-10-19T22:47:49.691447+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://mealfan.com/glp-1-statistics-2026\"},{\"cutoff_date\":null,\"display_name\":\"11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy\",\"first_seen_at\":\"2026-10-19T22:47:49.691457+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://gizmodo.com/11-of-americans-are-currently-taking-a-glp-1-weight-loss-drug-like-wegovy-2000782666\"},{\"cutoff_date\":null,\"display_name\":\"New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States\",\"first_seen_at\":\"2026-10-19T22:47:49.691462+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.rand.org/pubs/research_reports/RRA4153-1.html\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 drugs are making a dent in the high obesity rate in the U.S. : Shots - Health News : NPR\",\"first_seen_at\":\"2026-10-19T22:47:49.691467+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.npr.org/sections/shots-health-news/2025/10/28/nx-s1-5587805/glp-1-ozempic-zepbound-gallup-obesity-rate\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Statistics 2026: Use, Cost and Why People Stop - Vialie\",\"first_seen_at\":\"2026-10-19T22:47:49.691487+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://tryvialie.com/blog/glp-1-statistics\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Drug Use Triples In Two Years As American Obesity Rate Falls, Gallup Finds\",\"first_seen_at\":\"2026-10-19T22:47:49.691491+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.foreignpolicyjournal.com/2026/07/09/glp-1-drug-use-triples-in-two-years-as-american-obesity-rate-falls-gallup-finds\"},{\"cutoff_date\":null,\"display_name\":\"Foundayo (orforglipron)\",\"first_seen_at\":\"2026-10-19T22:47:49.691498+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://nowpatient.com/blog/foundayo-orforglipron-what-it-does-what-it-costs-and-how-to-access-it\"},{\"cutoff_date\":null,\"display_name\":\"Orforglipron Pill (Foundaro): Where to Get It, Cost, and More\",\"first_seen_at\":\"2026-10-19T22:47:49.691504+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.medicalnewstoday.com/articles/orforglipron-pill\"},{\"cutoff_date\":null,\"display_name\":\"ELI LILLY & Co - Form 8-K - FY2026\",\"first_seen_at\":\"2026-10-19T22:47:49.691508+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/q425lillysalesandearningsp.htm\"},{\"cutoff_date\":null,\"display_name\":\"Foundayo (orforglipron) FDA Approval History - Drugs.com\",\"first_seen_at\":\"2026-10-19T22:47:49.691512+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.drugs.com/history/foundayo.html\"},{\"cutoff_date\":null,\"display_name\":\"Orforglipron: FDA-Approved Weight Loss Pill Guide 2026\",\"first_seen_at\":\"2026-10-19T22:47:49.691515+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://bodevolvebariatric.com/orforglipron\"},{\"cutoff_date\":null,\"display_name\":\"Orforglipron (Foundayo): 2026 buyer's guide\",\"first_seen_at\":\"2026-10-19T22:47:49.691519+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://glpchart.com/drugs/orforglipron\"},{\"cutoff_date\":null,\"display_name\":\"Foundayo (Orforglipron): Cost & 2026 Label\",\"first_seen_at\":\"2026-10-19T22:47:49.691522+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://remyresearch.com/research/foundayo-orforglipron-fda-approved\"},{\"cutoff_date\":null,\"display_name\":\"Orforglipron FDA Decision 2026\",\"first_seen_at\":\"2026-10-19T22:47:49.691526+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://telehealthally.com/guides/orforglipron-fda-decision-tracker\"},{\"cutoff_date\":null,\"display_name\":\"Newest GLP-1 Drugs 2026: New Approvals & Pipeline\",\"first_seen_at\":\"2026-10-19T22:47:49.691529+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.weightlossrankings.org/research/newest-glp1-recent-approvals-launches\"},{\"cutoff_date\":null,\"display_name\":\"Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford\",\"first_seen_at\":\"2026-10-19T22:47:49.691537+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford\"},{\"cutoff_date\":null,\"display_name\":\"15% Of US Adults Have Used GLP-1s For Weight Loss, Poll Finds - KFF Health News\",\"first_seen_at\":\"2026-10-19T22:47:49.691541+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://kffhealthnews.org/morning-breakout/pharma-and-tech-070826\"},{\"cutoff_date\":null,\"display_name\":\"Appetite for Change - The Mehrotra Ledger\",\"first_seen_at\":\"2026-10-19T22:47:49.691544+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://themehrotraledger.substack.com/p/appetite-for-change\"},{\"cutoff_date\":null,\"display_name\":\"KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use\",\"first_seen_at\":\"2026-10-19T22:47:49.691547+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use\"},{\"cutoff_date\":null,\"display_name\":\"Public Opinion on Prescription Drugs and Their Prices\",\"first_seen_at\":\"2026-10-19T22:47:49.691551+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Usage Statistics 2026: Who's Taking Them — Calorilator\",\"first_seen_at\":\"2026-10-19T22:47:49.691555+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.calorilator.com/blog/glp-1-usage-statistics-2026\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Statistics 2026: Usage, Cost & Coverage Data\",\"first_seen_at\":\"2026-10-19T22:47:49.691560+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://therxindex.com/research/glp1-statistics\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Statistics & Trends: Usage, Market Size, Pricing & Research (2026)\",\"first_seen_at\":\"2026-10-19T22:47:49.691565+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.forbes.com/health/weight-loss/glp-1-statistics\"},{\"cutoff_date\":null,\"display_name\":\"As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze\",\"first_seen_at\":\"2026-10-19T22:47:49.691579+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.fool.com/investing/2026/10/11/as-glp-1-drugs-change-how-people-eat-drugmakers-co\"},{\"cutoff_date\":null,\"display_name\":\"U.S. Obesity Rate Drops as Use of GLP-1 Weight Loss Drugs Surges\",\"first_seen_at\":\"2026-10-19T22:47:49.691582+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.usnews.com/news/national-news/articles/2026-07-07/u-s-obesity-rate-drops-as-use-of-glp-1-weight-loss-drugs-surges\"},{\"cutoff_date\":null,\"display_name\":\"Novo Nordisk and Eli Lilly Just Got Some Fantastic News\",\"first_seen_at\":\"2026-10-19T22:47:49.691586+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://fool.com/investing/2026/10/16/novo-nordisk-and-eli-lilly-just-got-some-fantastic\"},{\"cutoff_date\":null,\"display_name\":\"11% of US Adults Take a GLP-1, Gallup Finds\",\"first_seen_at\":\"2026-10-19T22:47:49.691598+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://unusualwhales.com/news/glp1-use-11-percent-gallup-28-million\"},{\"cutoff_date\":null,\"display_name\":\"Obesity rate is declining as more Americans use weight loss drugs, survey finds\",\"first_seen_at\":\"2026-10-19T22:47:49.691603+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.yahoo.com/news/articles/obesity-rate-declining-more-americans-193902196.html\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 RA prescribing trends: June 2026\",\"first_seen_at\":\"2026-10-19T22:47:49.691607+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.truveta.com/blog/research/glp-1-ra-prescription-trends-january-2019-june-2026\"},{\"cutoff_date\":null,\"display_name\":\"The Oral GLP-1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch - Spherix Global Insights\",\"first_seen_at\":\"2026-10-19T22:47:49.691611+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.spherixglobalinsights.com/the-oral-glp-1-tracker-novos-oral-wegovy-hits-3m-prescription-milestone-as-lillys-foundayo-chugs-along-in-early-launch\"},{\"cutoff_date\":null,\"display_name\":\"Eli Lilly’s Foundayo Prescriptions Rise as Novo Nordisk’s Wegovy Pill Maintains Lead\",\"first_seen_at\":\"2026-10-19T22:47:49.691614+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://hlth.com/insights/news/eli-lilly-s-foundayo-prescriptions-rise-as-novo-nordisk-s-wegovy-pill-maintains-lead\"},{\"cutoff_date\":null,\"display_name\":\"What's actually in that black-market retatrutide vial?\",\"first_seen_at\":\"2026-10-19T22:47:49.691622+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://helainemknapp.substack.com/p/whats-actually-in-that-vial\"},{\"cutoff_date\":null,\"display_name\":\"The Oral GLP-1 Tracker: Prescriptions Edge Down For Novo, Lilly - News - Genohope\",\"first_seen_at\":\"2026-10-19T22:47:49.691625+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.genohopebio.com/news/the-oral-glp-1-wegovy-foundayo-85674724.html\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Pipeline 2026: Obesity Drug Timeline\",\"first_seen_at\":\"2026-10-19T22:47:49.691629+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://remyresearch.com/research/obesity-drug-pipeline-timeline-2026\"},{\"cutoff_date\":null,\"display_name\":\"The Oral GLP-1 Tracker: Novo's Wegovy pill vs Lilly's Foundayo\",\"first_seen_at\":\"2026-10-19T22:47:49.691632+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www-fiercepharma-com.translate.goog/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill?_x_tr_sl=en&_x_tr_tl=es&_x_tr_hl=es&_x_tr_pto=tc\"},{\"cutoff_date\":null,\"display_name\":\"2026 is the year GLP-1s grow up\",\"first_seen_at\":\"2026-10-19T22:47:49.691640+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.mmm-online.com/news/2026-is-the-year-glp-1s-grow-up\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up\",\"first_seen_at\":\"2026-10-19T22:47:49.691644+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 Users with Sleep Apnea Had About 40% Lower Acute Respiratory Failure Risk in Early CHEST Data\",\"first_seen_at\":\"2026-10-19T22:47:49.691648+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://medicaldaily.com/glp-1-sleep-apnea-acute-respiratory-failure-chest-2026-480137\"},{\"cutoff_date\":null,\"display_name\":\"How many Americans use weight loss drugs in 2026? - Heally\",\"first_seen_at\":\"2026-10-19T22:47:49.691651+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://getheally.com/patients/news/how-many-americans-are-using-weight-loss-drugs-in-2026\"},{\"cutoff_date\":null,\"display_name\":\"The Healthcare Economy\",\"first_seen_at\":\"2026-10-19T22:47:49.691659+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://jeffdelverne.substack.com/p/the-state-of-glp-1-usage-in-the-us\"},{\"cutoff_date\":null,\"display_name\":\"Charted: Are GLP-1s the solution to rising obesity rates?\",\"first_seen_at\":\"2026-10-19T22:47:49.691673+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.advisory.com/daily-briefing/2026/02/09/obestiy-rates\"},{\"cutoff_date\":null,\"display_name\":\"Who's Using GLP-1s? The 2026 Usage Numbers\",\"first_seen_at\":\"2026-10-19T22:47:49.691688+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.glpwinner.com/insights/whos-using-glp-1s-now-the-2026-numbers-explained\"},{\"cutoff_date\":null,\"display_name\":\"GLP-1 adoption promises to rewrite competition in pharma, consumer sectors\",\"first_seen_at\":\"2026-10-19T22:47:49.691696+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.emarketer.com/content/glp-1-adoption-promises-rewrite-competition-pharma--consumer-sectors\"},{\"cutoff_date\":null,\"display_name\":\"Eli Lilly (LLY) Q2 2026 Earnings Call Transcript\",\"first_seen_at\":\"2026-10-19T22:47:49.691702+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-q2-2026-032008362.html\"},{\"cutoff_date\":null,\"display_name\":\"Q2 2026 Earnings Call\",\"first_seen_at\":\"2026-10-19T22:47:49.691706+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://investor.lilly.com/static-files/ab69001c-650b-44f6-b629-309ee33f2335\"},{\"cutoff_date\":null,\"display_name\":\"Eli Lilly (LLY) Q2 2026 Earnings Call Transcript\",\"first_seen_at\":\"2026-10-19T22:47:49.691709+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.fool.com/earnings/call-transcripts/2026/08/12/eli-lilly-lly-q2-2026-earnings-call-transcript\"},{\"cutoff_date\":null,\"display_name\":\"Eli Lilly and Co (LLY) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% on Zepbound and ...\",\"first_seen_at\":\"2026-10-19T22:47:49.691712+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/eli-lilly-co-lly-q2-210754282.html\"},{\"cutoff_date\":null,\"display_name\":\"ELI LILLY AND COMPANY (LLY.MX) Q2 FY2026 earnings call transcript\",\"first_seen_at\":\"2026-10-19T22:47:49.691716+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/quote/LLY.MX/earnings/LLY.MX-Q2-2026-earnings_call-553767.html\"},{\"cutoff_date\":null,\"display_name\":\"LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?\",\"first_seen_at\":\"2026-10-19T22:47:49.691719+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://finance.yahoo.com/healthcare/articles/lly-around-6-post-robust-150900844.html\"},{\"cutoff_date\":null,\"display_name\":\"Lilly reports second-quarter 2026 financial results, raises ...\",\"first_seen_at\":\"2026-10-19T22:47:49.691722+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://investor.lilly.com/node/54781/pdf\"},{\"cutoff_date\":null,\"display_name\":\"Eli Lilly Q2 2026 slides: incretin revenue surges 67%, guidance raised By Investing.com\",\"first_seen_at\":\"2026-10-19T22:47:49.691728+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://za.investing.com/news/company-news/eli-lilly-q2-2026-slides-incretin-revenue-surges-67-guidance-raised-93CH-4409399\"},{\"cutoff_date\":null,\"display_name\":\"[Eli Lilly and Q2 2026 Earnings Call] Eli Lilly’s Incretin Sales Hit $14.9 Billion, Raising Full-Year Outlook to $87 Billion — BigGo Finance\",\"first_seen_at\":\"2026-10-19T22:47:49.691731+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://finance.biggo.com/news/US_LLY_2026-08-05\"},{\"cutoff_date\":null,\"display_name\":\"Medicare GLP-1 Bridge program enrolls over 600,000 beneficiaries\",\"first_seen_at\":\"2026-10-19T22:47:49.691734+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://thehill.com/opinion/healthcare/6121634-medicare-glp1-bridge-enrollment\"},{\"cutoff_date\":null,\"display_name\":\"Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?\",\"first_seen_at\":\"2026-10-19T22:47:49.691737+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.ajmc.com/view/medicare-glp-1-bridge-launches-but-who-actually-qualifies-\"},{\"cutoff_date\":null,\"display_name\":\"Medicare obesity drug GLP-1 coverage starting July 1\",\"first_seen_at\":\"2026-10-19T22:47:49.691740+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html\"},{\"cutoff_date\":null,\"display_name\":\"Medicare GLP-1 Bridge Program: Eligibility, Costs, and Coverage\",\"first_seen_at\":\"2026-10-19T22:47:49.691743+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.ncoa.org/article/expanding-access-to-weight-loss-medications-the-medicare-glp-1-bridge-program\"},{\"cutoff_date\":null,\"display_name\":\"What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge\",\"first_seen_at\":\"2026-10-19T22:47:49.691746+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid\"},{\"cutoff_date\":null,\"display_name\":\"Medicare and Weight-Loss Drugs: Coverage Expansion in 2026 - GoodRx\",\"first_seen_at\":\"2026-10-19T22:47:49.691750+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.goodrx.com/insurance/medicare/weight-loss-drugs\"},{\"cutoff_date\":null,\"display_name\":\"Medicare's $50 Per Month GLP-1 Bridge: What You Need to Know\",\"first_seen_at\":\"2026-10-19T22:47:49.691753+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.sheppard.com/insights/blogs/medicares-50-per-month-glp1-bridge-what-you-need-to-know\"},{\"cutoff_date\":null,\"display_name\":\"The Medicare GLP-1 Bridge: The Medicare Demonstration Program to Provide GLP-1 Medications for Obesity at $50 per Month Began July 1, 2026 - Caroline Fife M.D.\",\"first_seen_at\":\"2026-10-19T22:47:49.691756+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://carolinefifemd.com/2026/07/09/medicare-glp-1-bridge\"},{\"cutoff_date\":null,\"display_name\":\"Medicare's New GLP-1 Weight Loss Drug Program Launched July 1, but It Expires in 2027 with No Successor in Place\",\"first_seen_at\":\"2026-10-19T22:47:49.691759+00:00\",\"kind\":\"web\",\"provider\":\"anthropic\",\"snippet\":null,\"url\":\"https://www.medicaldaily.com/medicare-glp1-bridge-program-2026-balance-delay-coverage-2027-476283\"},{\"cutoff_date\":null,\"display_name\":\"kff.org\",\"first_seen_at\":\"2026-10-19T22:45:35.237516+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s\"},{\"cutoff_date\":null,\"display_name\":\"fda.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237523+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs\"},{\"cutoff_date\":null,\"display_name\":\"fda.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237531+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s\"},{\"cutoff_date\":null,\"display_name\":\"whitehouse.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237544+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients\"},{\"cutoff_date\":null,\"display_name\":\"investor.lilly.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237552+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://investor.lilly.com/news-releases/news-release-details/fda-approves-foundayotm-orforglipron-only-glp-1-pill-weight-loss-can\"},{\"cutoff_date\":null,\"display_name\":\"novonordisk-us.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237560+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916409\"},{\"cutoff_date\":null,\"display_name\":\"novonordisk-us.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237567+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.novonordisk-us.com/media/news-archive/news-details.html?id=918165\"},{\"cutoff_date\":null,\"display_name\":\"kff.org\",\"first_seen_at\":\"2026-10-19T22:45:35.237587+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.kff.org/medicaid/a-view-from-the-states-key-medicaid-policy-changes\"},{\"cutoff_date\":null,\"display_name\":\"fda.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237594+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize\"},{\"cutoff_date\":null,\"display_name\":\"fda.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237601+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.fda.gov/drugs/human-drug-compounding/fda-proposes-not-include-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list\"},{\"cutoff_date\":null,\"display_name\":\"federalregister.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237607+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\"},{\"cutoff_date\":null,\"display_name\":\"federalregister.gov\",\"first_seen_at\":\"2026-10-19T22:45:35.237614+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal\"},{\"cutoff_date\":null,\"display_name\":\"tevapharm.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237627+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.tevapharm.com/news-and-media/latest-news/teva-announces-launch-of-authorized-generic-of-victoza-liraglutide-injection-1.8mg-in-the-united-states\"},{\"cutoff_date\":null,\"display_name\":\"tevapharm.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237640+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.tevapharm.com/news-and-media/latest-news/teva-launches-first-generic-version-of-saxenda-liraglutide-injection-3mg-in-the-united-states\"},{\"cutoff_date\":null,\"display_name\":\"novonordisk.com\",\"first_seen_at\":\"2026-10-19T22:45:35.237651+00:00\",\"kind\":\"web\",\"provider\":\"tool\",\"snippet\":null,\"url\":\"https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=920329\"}],\"write_up\":\"## TL;DR\\n\\nMy forecast is **20% of U.S. adults** reporting current GLP-1 use for weight loss in Gallup’s qualifying 2030 release. The central 80% predictive interval is **12%–30%**. The forecast counts current users, not everyone who has tried these drugs, and is conditional on a comparable survey receiving a numerical resolution.\\n\\n## Context\\n\\nThe target is Gallup’s published percentage of all U.S. adults. Gallup first asks about ever taking the listed weight-loss medications, then asks affirmative respondents about current use; the reported population percentage does not use ever-users as its denominator ([Gallup questionnaire](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)). I forecast the first qualifying release, not a year-end prevalence or a prescription count.\\n\\nThe information cutoff is October 19, 2026. Historical observations anchor the forecast but do not resolve this future question. The numerical distribution is conditional on publication of a comparable measurement; survey discontinuation and annulment are not encoded as zero use.\\n\\n## Evidence\\n\\nThe full revised Gallup headline history is **3% current use and 6% ever-use in 2024; 8% and 12% in 2025; and 11% and 15% in 2026**. These are percentages of all adults, from the article published July 7, 2026, and updated September 8 after revised weighting ([Gallup revised series](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)). The latest wave surveyed 5,065 adults online through the probability-based Gallup Panel from May 28 through June 5, 2026; a subsequent analysis reused that wave rather than adding another observation ([Gallup follow-up](https://news.gallup.com/poll/713360/five-aspects-wellbeing-linked-glp-effectiveness.aspx)).\\n\\nThis is a short, imperfectly comparable history. The original survey covered March 4–9, 2024, with 5,577 respondents, and asked about injections using semaglutide and liraglutide as examples ([original release, May 21, 2024](https://news.gallup.com/poll/644861/injectable-weight-loss-drugs-uses-work.aspx)). The newer wording covers medications and also names tirzepatide ([updated questionnaire](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)). Three rounded annual observations establish rapid adoption. They do not identify a reliable saturation ceiling or prove that growth will keep slowing.\\n\\nAn independent survey supports the broad scale of adoption without matching Gallup’s definition. KFF’s complete current-use history is 6% in its April 23–May 1, 2024 survey, with 1,479 adults; 12% in October 27–November 2, 2025, with 1,350 adults; and 12% in February 24–March 2, 2026, with 1,343 adults. KFF includes use for diabetes and other conditions, not just weight loss, so I do not average these levels into Gallup’s series ([2024 methods](https://files.kff.org/attachment/Topline-KFF-Health-Misinformation-Tracking-Poll-May-2024.pdf), [2025 release](https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/), [March 2026 topline](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)). The 2025 survey also found that 22% of noncurrent users were interested in taking a GLP-1 for weight loss. That is a recruitment pool, not a conversion rate ([KFF demand findings](https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/)).\\n\\nCurrent use depends on both recruitment and continued treatment. A March 2026 claims study followed 33,607 commercially insured adults without diabetes who began Wegovy or Zepbound between January 1, 2021, and June 30, 2024. Its full one-year persistence history was 33.2% for 2021 initiators, N=889; 34.1% for 2022, N=2,480; 40.2% for 2023, N=14,665; and 60.9% for January–June 2024, N=15,573. Switching was allowed, and persistence used a 60-day treatment-gap rule. Follow-up extended through June 2025, so these are not outcomes for people starting in 2026 ([Marshall et al., JMCP](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/)). This is strong evidence against freezing early, poor persistence into a forecast of future use. It is not evidence of uninterrupted treatment through 2030.\\n\\nStopping is not necessarily permanent. A separate study published January 31, 2025, examined 125,474 initiators from January 2018 through December 2023. Among the 48,950 without diabetes, estimated one-year discontinuation was 64.8%; among eligible discontinuers without diabetes, estimated reinitiation within one year was 36.3%. The restart analysis was a selected subset, not all initiators ([Rodriguez et al., JAMA Network Open](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829779)). I therefore model starts, stops and restarts—not cumulative adoption multiplied by a permanent dropout rate.\\n\\nOral treatment is already part of the market. Wegovy pills reached U.S. distribution in January 2026, and FDA approved Foundayo/orforglipron on April 1, 2026, both before the latest Gallup fieldwork ([Novo launch-period data](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916566), [FDA approval letter](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000Approv.pdf)). Further penetration supports growth, but the entire launch effect cannot be credited again after the baseline. Affordability remains a constraint: the manufacturer’s price page lists oral Wegovy at $149 per month for the starter dose, versus $299 for the 9 mg and 25 mg doses. These are dose-specific nominal cash prices, not universal insured copays ([current manufacturer offer](https://www.novocare.com/patient/medicines/wegovy.html)).\\n\\nSupply and new products support the upper scenarios. On September 21, 2026, Novo announced an ambition to expand oral-obesity capacity tenfold by 2030. That is a global capacity ambition, not a count of future U.S. users ([Novo strategy announcement](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916773)). Lilly’s August 5 results said its retatrutide clinical package supported a planned U.S. submission in the first quarter of 2027. That is a development milestone, not an approval ([Lilly results](https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full)). I read these developments as making continued expansion feasible, without assuming every new product creates a new user rather than a switcher.\\n\\nCoverage is expanding unevenly. CMS launched Medicare GLP-1 Bridge on July 1, 2026, with a $50 monthly copay for eligible beneficiaries, but the program currently ends December 31, 2027 ([CMS launch release](https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications)). KFF’s June 29 analysis of 2023 claims estimated that 3.8 million beneficiaries met all eligibility criteria. The program is much narrower than universal Medicare obesity-drug coverage ([KFF eligibility analysis](https://www.kff.org/medicare/nearly-four-million-medicare-beneficiaries-could-be-eligible-for-the-temporary-medicare-glp-1-bridge-program-covering-these-drugs-for-weight-loss/)). Meanwhile, Mercer’s June 11 release reported that 6% of large employers were dropping weight-loss GLP-1 coverage in 2026, with another 5% planning or considering doing so in 2027. Its April 15–May 8 survey covered 604 organizations, including 481 with at least 500 employees; those percentages describe employers, not adults losing coverage ([Mercer survey](https://www.mercer.com/en-us/about/newsroom/employers-are-shifting-healthcare-costs-to-employees/)).\\n\\nMy numerical checks put moderated growth near one adult in five. Continuing the latest Gallup increase of three percentage points annually gives 23% after four years. Reducing each successive annual increment by 10% gives about 20%. Extending ever-use by three points annually produces 27% ever-use; holding the current/ever fraction at its latest value gives 19.8% current use. These are my calculations from the [revised Gallup history](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx), not fitted estimates of national transition rates. The current/ever fraction is a cross-sectional ratio, not individual retention.\\n\\nI turn those checks and the access evidence into the following judgmental mixture. Locations and standard deviations are percentage points of adults; each component is a normal distribution truncated to the physical 0%–100% range.\\n\\n| Scenario | Probability | Location | Standard deviation |\\n|---|---:|---:|---:|\\n| Access, safety or measurement setback | 5% | 7.5% | 3.0 points |\\n| Restricted access and substantial churn | 25% | 14.5% | 3.2 points |\\n| Continued, moderated expansion | 50.0% | 20.5% | 3.8 points |\\n| Rapid adoption with better access and persistence | 17% | 29% | 5.0 points |\\n| Very broad, low-cost adoption | 3% | 34% | 6.0 points |\\n\\nThese weights are forecasting judgments, not historical frequencies. Within-scenario spread includes adoption uncertainty, survey timing, sampling error and measurement drift; sampling error is not added again afterward. The resulting rounded mean and median are both 20%, with a central 90% interval of 9%–33%. The model assigns 9% probability to a published result at or below 11%, and 10% to a result at or above 30%. Today’s current-use level is not a floor.\\n\\n## What's non-obvious\\n\\nOne apparent contradiction in the historical evidence is largely a current-versus-ever problem. Gallup’s older obesity article described 12.4% as “taking” these drugs ([October 28, 2025 article](https://news.gallup.com/poll/696599/obesity-rate-declining.aspx)). But the chart preserved in Goodbody’s report explicitly asks whether respondents had **ever** taken them, showing 5.8% in early 2024 and 12.4% in 2025 ([preserved chart, printed page 45](https://www.ipha.ie/wp-content/uploads/2026/03/Pharma-in-Ireland-Goodbody-Report-for-IPHA-2026-1.pdf#page=46)). I exclude that figure from the current-use trend. It is not evidence that current use subsequently collapsed, or that weighting alone explains a huge revision.\\n\\n“New to the drug class” also need not mean a new person answering yes to Gallup. Novo’s launch analysis used a twelve-month prescription lookback and excluded compounded products when identifying prior GLP-1 treatment ([company data definitions](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916566)). I infer that its apparent new-user group can include restarters and people switching from compounded treatment. Pills expand access, but prescription growth cannot be translated one-for-one into additional survey users.\\n\\n## Uncertainties\\n\\nThe largest gaps are durable coverage after the temporary Medicare program, long-term persistence on oral products, and nationally representative stop–restart transitions. Existing persistence studies cover selected insured or clinical populations, not a matched sample of all adults ([CMS program terms](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge), [claims-study population](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/)). A longitudinal survey linked to dispensing data—including cash-pay and compounded treatment—would sharpen the forecast. I also could not verify a separate sample size and exact field window for the retrospective 2025 current-use point in the newer Gallup article ([Gallup series documentation](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)).\\n\\nReporting precision is another modeled uncertainty. I assign 85% probability to whole-percentage reporting and 15% to one-decimal reporting, reflecting the different formats in the [newer current-use release](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx) and [older obesity release](https://news.gallup.com/poll/696599/obesity-rate-declining.aspx). The code integrates over rounding intervals before assigning probability to the requested buckets. It places exactly zero probability below zero, puts a reported zero in the first nonnegative bucket, and retains outcomes above 40% rather than imposing an artificial ceiling.\"},\"engine\":{\"metadata\":{\"engine\":\"durable_forecast\",\"model\":\"gpt-6.1-sol\",\"model_route\":{\"deadline_seconds\":2400,\"managed_tools\":true,\"max_attempts\":2,\"metadata\":{},\"model\":\"gpt-6.1-sol\",\"native_code_execution\":true,\"native_web_search\":true,\"provider\":\"openai\",\"reasoning_effort\":\"xhigh\"},\"orchestration_backend\":\"durable_forecast\",\"provider\":\"openai\",\"question_type\":\"numeric\"},\"settings\":{\"claude_runtime\":\"e2b\",\"provider\":\"openai\",\"reasoning_effort\":\"high\",\"subforecast_count\":4,\"subforecast_model\":\"gpt-5.6-sol\",\"synthesis_model\":\"gpt-6.1-sol\",\"synthesis_reasoning_effort\":\"xhigh\"}},\"forecast\":{\"callsign\":\"LEGION22-02\",\"created_at\":\"2026-10-19T22:30:55.378302+00:00\",\"forecast_task_id\":\"5d25b6d5-5ad4-4488-badd-2e0318f34a08\",\"id\":\"60cdb97a-d3ee-4175-8d3c-39f0cfde0497\",\"orchestrator_model\":\"gpt-6.1-sol\",\"question_version_id\":\"768c451d-fad1-4452-9666-c441339e9f57\",\"research_model\":\"gpt-5.6-sol+gpt-6.1-sol+claude-opus-5-5\",\"trigger_kind\":\"featured\"},\"issuer\":\"Preseen\",\"product\":\"Preseen\",\"question\":{\"callsign\":\"LEGION22\",\"description\":\"This question asks what percentage of U.S. adults will report that they are currently taking GLP-1 medications for weight loss in Gallup's 2030 measurement, using the same definitions and survey methodology as the Gallup GLP-1 usage series. As of Gallup's most recent published update, self-reported current use for weight loss has increased substantially, reaching 11% of U.S. adults in 2026, up from 3% in 2024. ([news.gallup.com](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx))\\r\\n\\r\\nThe outcome is the percentage of U.S. adults who answer \\\"Yes\\\" to Gallup's current-use question for weight-loss medications (asked of respondents who indicate they have ever taken such medications), using Gallup's definitions and examples of GLP-1 medications in effect for the 2030 survey.\",\"fine_print\":\"The question concerns self-reported survey responses, not prescription, dispensing, insurance claims, or clinical utilization data. The resolved value is whatever Gallup publishes for the comparable statistic, regardless of subsequent revisions or methodological commentary unless Gallup itself replaces the originally published estimate with a corrected official value before resolution. If multiple 2030 Gallup releases report the same statistic from different survey waves, use the earliest publication in calendar year 2030.\",\"id\":\"151c25d1-c058-4ba2-9d1b-a321baa33445\",\"lower_bound\":\"0\",\"open_lower_bound\":false,\"open_upper_bound\":true,\"options\":[],\"options_are_comprehensive\":true,\"options_are_mutually_exclusive\":true,\"question_type\":\"numeric\",\"resolution_check_date\":null,\"resolution_criteria\":\"Resolve using the first Gallup News article published during calendar year 2030 (or, if none is published during 2030, the first Gallup publication thereafter reporting the 2030 survey results) that reports the percentage of U.S. adults who are currently taking GLP-1 medications for weight loss using the same Gallup survey series and definitions referenced by the user. ([news.gallup.com](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx))\\r\\n\\r\\nThe resolved value is the reported percentage of U.S. adults who currently take GLP-1 medications for weight loss. Use the published percentage exactly as reported by Gallup, including any decimal place(s) if provided. If Gallup changes the list of example medications while clearly intending to measure the same underlying concept of current GLP-1 use for weight loss, use the updated Gallup definition. If Gallup permanently discontinues the series before a 2030 measurement is conducted, the question is annulled.\",\"scale_type\":\"linear\",\"title\":\"What percentage of US adults will claim to be currently taking GLP-1 drugs for weight loss in 2030?\",\"upper_bound\":\"40\"},\"question_version\":{\"created_at\":\"2026-07-19T22:29:25.747312+00:00\",\"created_reason\":\"question_updated\",\"id\":\"768c451d-fad1-4452-9666-c441339e9f57\",\"version_number\":2},\"receipt_kind\":\"forecast_attestation\",\"receipt_schema_version\":1,\"signature_context\":{\"key_source\":\"configured\",\"public_key_id\":\"preseen-prod-ed25519-20260523\",\"signature_algorithm\":\"ed25519\",\"signed_at\":\"2026-10-19T22:59:26.551103+00:00\"}}","verification":{"valid":true,"error":""},"verify":{"public_keys_url":"https://preseen.com/api/v1/forecasts/attestation-keys/","steps":["Compute the SHA-256 of payload_canonical_json and compare it with payload_sha256.","Check signature over payload_canonical_json with public_key, then confirm public_key is a key Preseen publishes at the public keys address. A key you cannot match to one Preseen published does not show that Preseen signed the receipt.","When anchor_proof is present, check its RFC 3161 timestamp token against payload_sha256."]},"created_at":"2026-10-19T22:59:26.562536+00:00","updated_at":"2026-10-19T22:59:27.440167+00:00"}}